Wordt geladen...
Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation
Introduction: Crizotinib is a kinase inhibitor targeting c-MET/ALK/ROS1 used as the first-line chemical for the treatment of non-small cell lung cancer (NSCLC) with ALK mutations. Although c-MET is frequently overexpressed in 35-72% of NSCLC, most NSCLCs are primarily resistant to crizotinib treatme...
Bewaard in:
| Gepubliceerd in: | Int J Biol Sci |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Ivyspring International Publisher
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7415423/ https://ncbi.nlm.nih.gov/pubmed/32792859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijbs.45886 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|